(1/ )Summaries of the average high impact trial by field:
#EBM #medtwitter #epitwitter #FOAMed

#Cardiology:We enrolled the entire population of Europe in a trial to detect a composite endpoint occurring in 3% of patients. The relative risk reduction was 20%. The NNT is 12,000

(2/) #CritCare: We powered this trial assuming treatment would reduce mortality by 8000%. The primary outcome was not significant (p=0.06). However post hoc analysis of subgroup X was encouraging. A follow up trial but still inadequately powered trial is planned in this group.

(3/) #Oncology: We conducted a randomized trial of new drug X. The strengths of this study are BiOpLaUsiBiLitY. It was limited by a short-term surrogate primary outcome and lack of a control group. All authors have COI w/ drug manufacturer. The test article is now FDA approved.

(4/) #Surgery: These were my last 85 patients and what happened to them. I combined them with 3 of my friends' patients. Then we asked a statistician to propensity-score match, so this was basically a randomized trial.

#Nephrology: We tried to do a trial but no one would fund it.

(5/) #anesthesia: We asked if gas is good or bad. We are still not sure. Future studies will determine which is cooler: ultrasound or simulation.

#InfectiousDisease: We did a trial to see if you can shorten the course of abx. We found you can.